Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.
The Food & Drug Administration (FDA) announced its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady ...
PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...
Canoga Park, California, June 02, 2025 (GLOBE NEWSWIRE) -- Aegis Treatment Centers, part of the Pinnacle Treatment Centers Family of Companies, a leader in providing evidence-based care for ...
Earnings call Indivior reported 2025 net revenue of $1.24B (+4% YoY) and record SUBLOCADE revenue of $856M (+13% YoY), with adjusted EBITDA up 20%. For 2026, management guides for mid-teens SUBLOCADE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results